MARKETSPERPSLIVE82
Cash
Portfolio
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science
PredictLive82AccountSocial
Product
Kalshi ProPerpetual FuturesMarketsIncentive programInstitutionsAPI & developers
Company
AboutKalshi ResearchBlogCareersPolicy CenterBrand Kit
Help
Help CenterFAQFee scheduleTrading hoursRegulatoryTrust Center
© 2026 Kalshi Inc. · All rights reserved
PrivacyData Terms of ServiceTrading ProhibitionsFAQ for Finance Professionals
Trading on Kalshi involves risk and may not be appropriate for all. Members risk losing their cost to enter any transaction, including fees. You should carefully consider whether trading on Kalshi is appropriate for you in light of your investment experience and financial resources. Any trading decisions you make are solely your responsibility and at your own risk. Information is provided for convenience only on an "AS IS" basis. Past performance is not necessarily indicative of future results. Kalshi is subject to U.S. regulatory oversight by the CFTC.
TrendingElectionsPoliticsCultureSportsCryptoCommoditiesClimateEconomicsMentions

Finance

Tech & Science

Biotech

All markets
Public Companies Hub
Companies
Indices
Industries
Biotech
Compute
Markets
Biotech

FDA decision: Brepocitinib by Priovant Therapeutics (this year)

Yes
1.14x
No
4.98x
$4,111 vol1 market
Biotech

FDA decision: Bepirovirsen by GlaxoSmithKline (this year)

Yes
1.29x
No
3.08x
$254 vol1 market
Biotech

FDA decision: Venglustat by Sanofi (this year)

Yes
1.16x
No
4.51x
$452 vol1 market
Biotech

FDA decision: Saroglitazar by Zydus Therapeutics (this year)

Yes
1.33x
No
2.98x
$351 vol1 market
Biotech

FDA decision: Rusfertide by Protagonist Therapeutics (this year)

Yes
1.09x
No
6.29x
$1,640 vol1 market
Biotech

FDA decision: Ivonescimab by Summit Therapeutics (this year)

Yes
1.52x
No
2.40x
$4,218 vol1 market
Biotech

FDA decision: Ifinatamab Deruxtecan by Daiichi Sankyo (this year)

Yes
1.22x
No
3.80x
$468 vol1 market
Biotech

FDA decision: DTX401 (pariglasgene brecaparvovec) by Ultragenyx Pharmaceutical (this year)

Yes
1.42x
No
2.52x
$2,278 vol1 market
Biotech

FDA decision: bictegravir 75 mg/lenacapavir 50 mg (BIC/LEN) by Gilead Sciences (this year)

Yes
1.04x
No
8.56x
$666 vol1 market
Biotech

FDA decision: BBP-418 by Ml Bio Solutions Inc. (this year)

Yes
1.06x
No
7.85x
$642 vol1 market
Biotech

FDA decision: Anitocabtagene Autoleucel (anito-cel) by Gilead Sciences (this year)

Yes
1.22x
No
3.80x
$858 vol1 market